The European Commission Has Approved BeiGene's For Brukinsa (Zanubrutinib) In Combination With Obinutuzumab For Relapsed Or Refractory Follicular Lymphoma Who Have Received At Least Two Prior Lines Of Systemic Therapy

0.00%

BeiGene Ltd. Sponsored ADR

BGNE

0.00

This marks the fourth indication in the European Union (EU) for BRUKINSA, which is now approved to treat more patient populations in the EU than any other Bruton's tyrosine kinase (BTK) inhibitor.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.

Recommend

Trading Wisdom | How To Pick Dividend Stocks

Will Diodes’ (DIOD) New Automotive LED Controller Strengthen Its Position in Vehicle Display Technology?

CTS (CTS): Assessing Valuation After Strong Revenue Growth and Upgraded Outlook

How Dollar General's (DG) New COO and Leadership Changes Have Shifted Its Investment Narrative

SS&C Technologies (SSNC): Exploring Valuation After Recent Steady Share Climb

First Financial Bancorp (FFBC): Evaluating Valuation Following Gator Capital’s New Investment and Analyst Optimism

Stryker (SYK): Exploring Valuation Ahead of Potential Market Shifts

Options Corner: Google’s Taking Over from Nvidia in the AI Game! Let Me Break Down Google’s Cash-Secured Puts Strategy for You